Press Release | October 11, 2022
DICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for Psoriasis
Read More
Press Release | October 3, 2022
Metagenomi Announces Opening of Manufacturing Facility for its Next Generation CRISPR Gene-Editing Systems and Therapies
Read More
News | September 22, 2022
Affini-T Therapeutics Named to the 2022 Endpoints 11
Read More
News | September 22, 2022
Metagenomi Named an Endpoints 11 Winner
Read More
